Who is sponsoring NCT03717545?

NCT03717545 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03717545?

Interventions in NCT03717545: second allogeneic stem cell transplantation.

What condition does NCT03717545 study?

NCT03717545 studies Graft Failure, Stem Cell Transplant Complications.

Is NCT03717545 still recruiting?

NCT03717545 is currently status unknown. Last updated 24 September 2020.

Last reviewed 2020-09-24 · How we verify

NCT03717545

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Second Transplantation for Graft Failure

Status unknown NA Last updated 24 September 2020

What this trial tests

NA trial testing second allogeneic stem cell transplantation in Graft Failure in 12 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 March 2018
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

second allogeneic stem cell transplantation

Conditions studied

Graft Failure — all drugs for Graft Failure →
Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →

Sponsor

Peking University People's Hospital

Who can join

Eligibility, any sex, with Graft Failure or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Graft failure is a lethal complication after allogeneic stem cell transplantation, which often need a salvage transplantation. However, the current outcome of second transplantation for graft failure is far from satisfactory. We performed a prospective single-arm study to investigate the safety and efficacy of a novel regimen.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.
Sun YQ, Wang Y, Wang FR, Yan CH, et al · · 2021 · cited 17× · PMID 34150785 · DOI 10.3389/fmed.2021.604085
Advances in second hematopoietic stem cell transplantation.
Yan S, Zhu X, Xiao Y. · · 2024 · cited 1× · PMID 39044835 · DOI 10.3389/fimmu.2024.1428101

Verify or expand the search:

Other trials of second allogeneic stem cell transplantation

Trials testing the same drug.

NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting

Other recruiting trials for Graft Failure

Currently open trials in the same condition.

NCT06800430 — Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery · recruiting
NCT06872333 — Allo HSCT for High Risk Hemoglobinopathies · Phase 2 · recruiting
NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting
NCT06676696 — Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to S · Phase 4 · recruiting
NCT06179329 — One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein Grafts in Women Undergoing Isolated CABG · NA · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717545 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 24 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing